Introduction
The DNA tumour viruses including adenovirus, polyomavirus/simian virus 40 (SV40) and the human papillomavirus possess the capacity to transform cells oncogenically in culture [ 11, and indeed the papillomaviruses represent an important causative agent for human cervical carcinoma [Z] .
Nevertheless, the oncogenic properties of the DNA tumour viruses are actually a byproduct of a nonproductive lytic infection. The normal goal of these viruses is to replicate and produce new virus. Moreover, the activities that are involved in the oncogenic capacity of theses viruses must function normally to facilitate lytic growth. Indeed, it would appear that it is the strategy that these viruses have developed to achieve a replicative cycle in a quiescent cell that probably also results in oncogenic transformation when a lytic infection cannot proceed. Recent events have revealed details of these mechanisms, including the ability of these viruses to Abbreviations used: Rb. retinoblastoma; SV40, simian virus 40.
inactivate key regulatory proteins involved in cellgrowth control. Most importantly, an understanding of these events in the context of the lytic infection has shed light on the manner by which these viruses can cause oncogenic transformation and cancer.
Disruption of E2F regulation by the DNA tumour viruses
One strategy that was directed at the identification of targets for the action of the adenovirus E1A protein involved the analysis of proteins in physical association with E 1A as judged by co-immunoprecipitation. These studies revealed a series of cellular proteins in physical association with E1A [ 3 , 41.
Although originally identified as a series of bands in SDS/polyacrylamide gels (see Figure 1 a) , subsequent analyses demonstrated that one of these E 1A-associated proteins, a protein of 105 kDa, was the product of the retinoblastoma (Rb) tumour suppressor gene [5] . This finding was of great importance in focusing attention on the relationship between the action of a viral oncoprotein with a
I993
Biochemical Society Transactions Subsequent experiments demonstrated that both the SV40 T-antigen and the human papillomavirus E7 product could also be found to associate with Rb as well as with many of the other E l A-associated proteins [ 10, 111. Clearly, the DNA tumour virus oncogenic products possess a common ability to bind to key cellular regulatory proteins. Moreover, since the ability of E1A to associate with proteins such as the Rb gene product was found to be dependent on E1A protein sequences that were important for oncogenic activity [ 121, it appeared that this property (association with Rb) was a reflection of its oncogenic capacity.
Other experiments directed at the action of E1A as a transcriptional regulatory protein, provided a context in which to view the action of ElA, T-antigen and E7 in targeting the Rb protein. The analysis of mechanisms of transcription of the early adenovirus E2 gene identified a cellular transcription factor termed E2F that was essential for the E 1 A-mediated activation of E2 transcription [ 131. Later experiments demonstrated an interaction of E2F with other cellular proteins that inhibited the ability of E2F to stimulate E2 transcription [14] .
This study also demonstrated that the E1A protein could disrupt these E2F complexes, releasing an E2F that was free of previous interactions and that could activate transcription.
Through the use of specific antibodies, it became clear that one of the proteins in association with E2F was the Rb gene product [15] [16] [17] [18] . It appears that the interaction of E1A with Rb, as originally detected in co-immunoprecipitation assays (Figure la) , is a reflection of the ability of E1A to disrupt the E2F-Rb complex (Figure lb) . Moreover, many of the other proteins identified as E 1 A-associated proteins, including the Rb-related p107 protein, cyclin A and cdk2 kinase, were also found in complexes with E2F. Indeed, at least four distinct E2F complexes, schematically depicted in Figure 2 , have now been identified in cell extracts. One complex contains the Rb protein, while a second complex, which accumulates during the S phase of the cell cycle, contains the Rb-related p107 protein together with cyclin A and the cdk2 kinase [19] [20] [21] [22] [23] [24] . Finally, at least two complexes have been detected in G, phase cell extracts, one containing E2F in association with p107 [25] , and another containing the same components as well as the cyclin E protein and the cdk2 kinase [26] .
It is now clear that SV40 T-antigen and human papillomavirus E7, as well as ElA, can dissociate the E2F complexes, releasing free E2F and leaving the viral proteins bound to the Rb protein Volume 
21
Signalling from the Plasma Membrane t o the Nucleus [27] . Thus, the common activity of ElA, T-antigen and E7 that allows the binding to the Rb protein appears to reflect the ability of these viral proteins to release E2F from complexes containing the Rb protein ( Figure 1) 
Evolution of a common viral activity
Whereas the activation of E2F by E1A makes sense for adenovirus transcription, given the role of E2F in transcription of the viral E2 gene 
E2F?
A possible answer lies in the identification of the cellular genes that appear to use E2F. This group of genes shares common regulatory properties and also encodes proteins with related activities [36] . Each of these genes is activated in late G, as a quiescent cell is stimulated to re-enter the growth cycle. Moreover, with the possible exception of cmyb for which a function of the product has not yet been determined, each gene encodes a protein that plays a role in producing the appropriate environment for DNA replication to occur. In this context, an activation of E2F leading to an activation of these S phase genes, may represent the common ground shared by these three DNA tumour viruses. It has been known for over twenty years that adenovirus, SV40 and polyomavirus can induce a quiescent cell to enter S phase and that this is dependent on E l A or T-antigen function [37] . Together with the entry into S phase is an activation of various activities that encode S phase functions. Many of these genes contain E2F-binding sites and direct experiments have shown a role for E2F in the activation of the dihydrofolate reductase gene, which leads to the speculation that the ability of ElA, T-antigen and E7 to activate E2F may be responsible for the ability of these viruses to induce a quiescent cell to enter S phase and thus promote the replication of the viral DNA.
The experiments outlined above suggest that the E2F transcription factor may be a significant target for the DNA tumour virus oncoproteins in driving a quiescent cell into S phase. These viruses are genetically distinct, and the appearance of genes such as ElA, T-antigen and E7 in these viruses undoubtedly represents independent evolutionary events. If the action of these viral proteins is to induce S phase in an otherwise quiescent cell, through the activation of the E2F transcription factor, then the fact that this process has evolved independently three times suggests that the activation of E2F may be a critical event in the normal progression of a quiescent cell to S phase, This possibility is strengthened further by the recent observation that overexpression of the E2F1 cDNA in quiescent cells, as a result of the microinjection of an E2F1-encoding plasmid, results in the stimulation of DNA synthesis in these otherwise quiescent cells [ 381. These results, together with the previous observations of the ability of E1A and T-antigen to induce cellular proliferation, suggest the possibility that E2F is indeed a critical regulatory factor in mediating cellular growth control.
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Conclusions
The studies outlined in this report highlight how useful the DNA tumour viruses can be in the elucidation of complex cellular regulatory events. Indeed, in many respects, the DNA tumour viruses have provided many of the key clues concerning the molecular events that are involved in mammalian-cell-growth control. Further study of the regulation of the mechanism of action of the E2F transcription factor will undoubtedly help t o illuminate the complex series of regulatory steps involved in regulating
